TARA

Protara Therapeutics, Inc.

Price Chart

Latest Quote

$3.98

-0.09 (-2.21%)

Current Price

Previous Close	$4.07
Open	$4.13
Day High	$4.20
Day Low	$3.97
Volume	803,685

Fetched: 2026-06-19T01:40:20

Stock Information

Shares Outstanding	56.20M
Total Debt	$3.06M
Cash Equivalents	$135.79M
Net Income	$-63.31M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$223.69M
EPS (TTM)	$-1.36
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$81.41M
Income	$-63.31M
Book/sh	$3.67
Cash/sh	$2.42
Employees	46

Financial Ratios

Quick Ratio	15.39
Current Ratio	15.69
Debt/Eq	1.69

Returns & Margins

ROA	-24.29%
ROE	-37.27%

Ownership

Insider Ownership	2.42%
Institutional Ownership	82.37%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.42
P/B	1.09

Analyst Data

Recommendation	strong_buy
Target Price	$26.57

Technical Indicators

SMA20	$4.28
SMA50	$4.82
SMA200	$5.26
RSI	34.42
ATR	0.2517

Shares Float	49.46M
Short Float	10.66%
Short Ratio	7.52
Volatility	1.45
Rel Volume	0.99

Performance History

Week	+9.04%
Month	-8.29%
Quarter	-24.91%
6 Months	-26.57%
YTD	-26.02%
Year	+30.07%
3 Years	+42.14%
5 Years	-60.04%
10 Years	-98.08%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$3.98	803,685
2026-06-17	$4.07	820,000
2026-06-16	$3.81	510,700
2026-06-15	$3.94	494,600
2026-06-12	$3.90	524,500
2026-06-11	$3.65	1,468,300
2026-06-10	$3.78	820,800
2026-06-09	$3.97	982,600
2026-06-08	$4.04	730,500
2026-06-05	$4.16	442,500
2026-06-04	$4.41	377,600
2026-06-03	$4.22	515,700
2026-06-02	$4.34	513,000
2026-06-01	$4.52	742,600
2026-05-29	$4.65	554,700
2026-05-28	$4.75	703,200
2026-05-27	$4.76	702,800
2026-05-26	$4.80	828,300
2026-05-22	$4.92	1,130,300
2026-05-21	$4.97	2,515,800
2026-05-20	$4.76	704,400
2026-05-19	$4.34	497,200

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

📰 Latest News

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Motley Fool • 2026-05-31T14:39:50Z

One Protara Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St. • 2026-05-04T10:15:08Z

Protara Therapeutics: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-10T12:10:42Z

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf

MarketBeat • 2026-03-02T01:36:34Z

Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU

MarketBeat • 2026-02-25T08:12:25Z

Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%

Simply Wall St. • 2025-11-24T13:17:34Z

Protara Therapeutics: Q3 Earnings Snapshot

Associated Press Finance • 2025-11-10T13:06:53Z

Protara Therapeutics, Inc. (NASDAQ:TARA) is favoured by institutional owners who hold 74% of the company

Simply Wall St. • 2025-10-28T12:57:52Z

A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index

Simply Wall St. • 2025-09-24T11:27:55Z

What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders

Simply Wall St. • 2025-09-22T10:36:35Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$64,549,000	$49,154,000	$43,613,000	$37,545,000
Other Income Expense	$779,000	$423,000	$12,000	$-29,500,000
Other Non Operating Income Expenses	$730,000	$387,000	-	-
Net Non Operating Interest Income Expense	$6,331,000	$4,135,000	$3,181,000	$1,093,000
Operating Expense	$64,549,000	$49,154,000	$43,613,000	$37,545,000
General And Administrative Expense	$21,916,000	$17,450,000	$18,624,000	$20,737,000
Interest Expense	-	-	-	$1,137,000
Interest Expense Non Operating	-	-	-	$1,137,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Net Interest Income	$6,331,000	$4,135,000	$3,181,000	$1,093,000
Interest Income	$6,331,000	$4,135,000	$3,181,000	$2,230,000
Normalized Income	$-57,488,000	$-44,632,000	$-40,432,000	$-36,452,000
Net Income From Continuing And Discontinued Operation	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Total Operating Income As Reported	$-64,549,000	$-49,154,000	$-43,613,000	$-67,062,000
Net Income Common Stockholders	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Net Income	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Net Income Including Noncontrolling Interests	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Net Income Continuous Operations	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Pretax Income	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Interest Income Non Operating	$6,331,000	$4,135,000	$3,181,000	$2,230,000
Operating Income	$-64,549,000	$-49,154,000	$-43,613,000	$-37,545,000
Special Income Charges	-	-	$0	$-29,517,000
Per Share
Diluted EPS	$-1.34	$-2.17	$-3.57	$-5.86
Basic EPS	$-1.34	$-2.17	$-3.57	$-5.86
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-64,236,000	$-48,858,000	$-43,284,000	$-35,067,000
Total Unusual Items	$49,000	$36,000	$12,000	$-29,500,000
Total Unusual Items Excluding Goodwill	$49,000	$36,000	$12,000	$-29,500,000
Reconciled Depreciation	$362,000	$332,000	$341,000	$248,000
EBITDA (Bullshit earnings)	$-64,187,000	$-48,822,000	$-43,272,000	$-64,567,000
EBIT	$-64,549,000	$-49,154,000	$-43,613,000	$-64,815,000
Diluted Average Shares	$42,836,129	$20,592,847	$11,331,338	$11,259,615
Basic Average Shares	$42,836,129	$20,592,847	$11,331,338	$11,259,615
Diluted NI Availto Com Stockholders	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Gain On Sale Of Security	$49,000	$36,000	$12,000	$17,000
Research And Development	$42,633,000	$31,704,000	$24,989,000	$16,808,000
Selling General And Administration	$21,916,000	$17,450,000	$18,624,000	$20,737,000
Other Gand A	$21,916,000	$17,450,000	$18,624,000	$20,737,000
Impairment Of Capital Assets	-	-	$0	$29,517,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$193,482,000	$163,889,000	$65,660,000	$101,999,000
Total Assets	$209,468,000	$181,454,000	$78,954,000	$113,290,000
Total Non Current Assets	$49,964,000	$9,299,000	$10,249,000	$27,144,000
Other Non Current Assets	$765,000	$772,000	$756,000	$761,000
Investmentin Financial Assets	$42,336,000	$0	$0	$17,886,000
Goodwill And Other Intangible Assets	$2,930,000	$3,245,000	$2,661,000	$84,000
Other Intangible Assets	$2,930,000	$3,245,000	$2,661,000	$84,000
Current Assets	$159,504,000	$172,155,000	$68,705,000	$86,146,000
Other Current Assets	$65,000	$2,000	$37,000	$127,000
Prepaid Assets	$2,628,000	$1,861,000	$2,846,000	$1,163,000
Receivables	$1,257,000	$0	$242,000	$486,000
Accrued Interest Receivable	$1,257,000	$0	$242,000	$486,000
Cash Cash Equivalents And Short Term Investments	$155,554,000	$170,292,000	$65,580,000	$84,370,000
Cash And Cash Equivalents	$49,657,000	$162,798,000	$39,586,000	$24,127,000
Non Current Prepaid Assets	-	$0	$272,000	$544,000
Restricted Cash	-	-	-	-
Debt
Total Debt	$3,359,000	$4,483,000	$5,467,000	$6,384,000
Long Term Debt And Capital Lease Obligation	$2,117,000	$3,359,000	$4,484,000	$5,467,000
Current Debt And Capital Lease Obligation	$1,242,000	$1,124,000	$983,000	$917,000
Liabilities
Total Liabilities Net Minority Interest	$13,056,000	$14,320,000	$10,633,000	$11,207,000
Total Non Current Liabilities Net Minority Interest	$2,117,000	$3,359,000	$4,484,000	$5,467,000
Current Liabilities	$10,939,000	$10,961,000	$6,149,000	$5,740,000
Payables And Accrued Expenses	$6,430,000	$7,304,000	$3,054,000	$2,280,000
Payables	$3,468,000	$4,429,000	$2,434,000	$1,586,000
Accounts Payable	$3,468,000	$4,429,000	$2,434,000	$1,586,000
Total Tax Payable	-	-	-	-
Equity
Common Stock Equity	$196,412,000	$167,134,000	$68,321,000	$102,083,000
Total Equity Gross Minority Interest	$196,412,000	$167,134,000	$68,321,000	$102,083,000
Stockholders Equity	$196,412,000	$167,134,000	$68,321,000	$102,083,000
Gains Losses Not Affecting Retained Earnings	$90,000	$2,000	$-31,000	$-688,000
Other Equity Adjustments	$90,000	$2,000	$-31,000	$-688,000
Retained Earnings	$-302,419,000	$-244,980,000	$-200,384,000	$-159,964,000
Other
Ordinary Shares Number	$53,587,260	$35,044,772	$11,364,903	$11,267,389
Share Issued	$53,587,260	$35,044,772	$11,364,903	$11,267,389
Tangible Book Value	$193,482,000	$163,889,000	$65,660,000	$101,999,000
Invested Capital	$196,412,000	$167,134,000	$68,321,000	$102,083,000
Working Capital	$148,565,000	$161,194,000	$62,556,000	$80,406,000
Capital Lease Obligations	$3,359,000	$4,483,000	$5,467,000	$6,384,000
Total Capitalization	$196,412,000	$167,134,000	$68,321,000	$102,083,000
Additional Paid In Capital	$498,687,000	$412,077,000	$268,725,000	$262,724,000
Capital Stock	$54,000	$35,000	$11,000	$11,000
Common Stock	$54,000	$35,000	$11,000	$11,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$2,117,000	$3,359,000	$4,484,000	$5,467,000
Current Capital Lease Obligation	$1,242,000	$1,124,000	$983,000	$917,000
Pensionand Other Post Retirement Benefit Plans Current	$3,267,000	$2,533,000	$2,112,000	$2,543,000
Current Accrued Expenses	$2,962,000	$2,875,000	$620,000	$694,000
Investments And Advances	$42,336,000	$0	$0	$17,886,000
Available For Sale Securities	$42,336,000	-	-	$17,886,000
Net PPE	$3,933,000	$5,282,000	$6,560,000	$7,869,000
Accumulated Depreciation	$-1,468,000	$-1,106,000	$-824,000	$-483,000
Gross PPE	$5,401,000	$6,388,000	$7,384,000	$8,352,000
Leases	$553,000	$553,000	$553,000	$553,000
Other Properties	$4,153,000	$5,248,000	$6,232,000	$7,242,000
Machinery Furniture Equipment	$695,000	$587,000	$599,000	$557,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$105,897,000	$7,494,000	$25,994,000	$60,243,000
Treasury Shares Number	-	-	$0	-
Goodwill	-	-	-	$0

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-56,459,000	$-35,871,000	$-37,602,000	$-26,577,000
Operating Activities
Operating Cash Flow	$-56,365,000	$-35,808,000	$-37,557,000	$-26,457,000
Cash Flow From Continuing Operating Activities	$-56,365,000	$-35,808,000	$-37,557,000	$-26,457,000
Operating Gains Losses	$-9,000	-	-	-
Investing Activities
Capital Expenditure	$-94,000	$-63,000	$-45,000	$-120,000
Investing Cash Flow	$-139,491,000	$19,155,000	$53,107,000	$14,950,000
Cash Flow From Continuing Investing Activities	$-139,491,000	$19,155,000	$53,107,000	$14,950,000
Financing Activities
Issuance Of Capital Stock	$80,964,000	$136,006,000	$0	-
Financing Cash Flow	$82,715,000	$139,865,000	$-91,000	$-90,000
Cash Flow From Continuing Financing Activities	$82,715,000	$139,865,000	$-91,000	$-90,000
Net Other Financing Charges	$-799,000	$-83,000	$-91,000	-
Net Common Stock Issuance	$80,964,000	$136,006,000	$0	$-90,000
Common Stock Issuance	$80,964,000	$136,006,000	$0	-
Repurchase Of Capital Stock	-	-	$-91,000	$-90,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Interest Paid Supplemental Data	$0	$0	$0	$0
Income Tax Paid Supplemental Data	$0	$0	$0	$0
End Cash Position	$50,402,000	$163,543,000	$40,331,000	$24,872,000
Beginning Cash Position	$163,543,000	$40,331,000	$24,872,000	$36,469,000
Changes In Cash	$-113,141,000	$123,212,000	$15,459,000	$-11,597,000
Proceeds From Stock Option Exercised	$2,550,000	$3,942,000	$0	-
Net Investment Purchase And Sale	$-139,397,000	$19,218,000	$53,152,000	$15,070,000
Sale Of Investment	$65,234,000	$48,600,000	$65,338,000	$58,620,000
Purchase Of Investment	$-204,631,000	$-29,382,000	$-12,186,000	$-43,550,000
Net PPE Purchase And Sale	$-94,000	$-63,000	$-45,000	$-120,000
Purchase Of PPE	$-94,000	$-63,000	$-45,000	$-120,000
Change In Working Capital	$-2,941,000	$4,007,000	$-4,139,000	$539,000
Change In Other Current Liabilities	$-1,124,000	$-984,000	$-917,000	$-1,327,000
Change In Other Current Assets	$322,000	$-328,000	$-2,300,000	$222,000
Change In Payables And Accrued Expense	$-52,000	$4,057,000	$343,000	$1,379,000
Change In Accrued Expense	$821,000	$2,676,000	$-505,000	$748,000
Change In Payable	$-873,000	$1,381,000	$848,000	$631,000
Change In Account Payable	$-873,000	$1,381,000	$848,000	$631,000
Change In Prepaid Assets	$-2,087,000	$1,262,000	$-1,265,000	$265,000
Other Non Cash Items	$1,081,000	$1,009,000	$1,013,000	$1,366,000
Stock Based Compensation	$3,826,000	$4,125,000	$6,092,000	$6,688,000
Amortization Of Securities	$-1,245,000	$-685,000	$-444,000	$1,137,000
Depreciation Amortization Depletion	$362,000	$332,000	$341,000	$248,000
Depreciation And Amortization	$362,000	$332,000	$341,000	$248,000
Depreciation	$362,000	$332,000	$341,000	$248,000
Gain Loss On Investment Securities	$-9,000	-	-	-
Net Income From Continuing Operations	$-57,439,000	$-44,596,000	$-40,420,000	$-65,952,000
Common Stock Payments	-	-	$-91,000	$-90,000
Asset Impairment Charge	-	-	$0	$29,517,000
Repayment Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Short Term Debt Issuance	-	-	-	-
Short Term Debt Payments	-	-	-	-

Fetched: 2026-06-17